In post hoc analyses of the randomised clinical controlled LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial, patients assigned to GLP-1RAs (liraglutide) had a reduced risk of prostate cancer (HR 0.54, 95% CI 0.34, 0.88) compared with patients assigned to placebo in addition to standard care
Sivertsen, J., Rosenmeier, J., Holst, J
the GLP-1 semaglutide reduced the risk of major adverse cardiovascular events vs comparators in a broad T2DM population [9]
This is never normal and always requires evaluation
GLP-1 Analogs When choosing a GLP-1 receptor agonist, options include long-acting vs short-acting agents, the need for reconstitution, patient preference, health insurance coverage & cost to the patient
The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS Clinical Trials